

# Kyoung Mee Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2951661/publications.pdf>

Version: 2024-02-01

329  
papers

14,827  
citations

25034

57  
h-index

27406

106  
g-index

337  
all docs

337  
docs citations

337  
times ranked

17553  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nature Medicine</i> , 2015, 21, 449-456.	30.7	1,592
2	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	30.7	1,071
3	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 268-273.	1.6	667
4	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 3130-3136.	1.6	370
5	Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. <i>Gut</i> , 2014, 63, 236-243.	12.1	309
6	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	1.6	293
7	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 37-48.	9.4	248
8	Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. <i>Cancer Research and Treatment</i> , 2012, 44, 157-165.	3.0	180
9	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. <i>Nature Genetics</i> , 2018, 50, 979-989.	21.4	168
10	Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. <i>Nature Communications</i> , 2014, 5, 5477.	12.8	166
11	Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virus-Associated Gastric Carcinoma. <i>Gastroenterology</i> , 2010, 139, 84-92.e2.	1.3	162
12	Comparing MR Imaging and CT in the Staging of Gastric Carcinoma. <i>American Journal of Roentgenology</i> , 2000, 174, 1551-1557.	2.2	159
13	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019, 9, 1388-1405.	9.4	155
14	A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial†. <i>Annals of Oncology</i> , 2021, 32, 368-374.	1.2	153
15	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	7.0	152
16	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <i>Nature Genetics</i> , 2018, 50, 1399-1411.	21.4	145
17	Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. <i>Cancer Research and Treatment</i> , 2016, 48, 1155-1166.	3.0	142
18	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377.	12.8	137

#	ARTICLE	IF	CITATIONS
19	Low-level microsatellite instability in most colorectal carcinomas. <i>Cancer Research</i> , 2002, 62, 1166-70.	0.9	135
20	Deregulation of Immune Response Genes in Patients With Epstein-Barr Virus-Associated Gastric Cancer and Outcomes. <i>Gastroenterology</i> , 2015, 148, 137-147.e9.	1.3	127
21	Molecular Features of Colorectal Hyperplastic Polyps and Sessile Serrated Adenoma/Polyps From Korea. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1274-1286.	3.7	117
22	MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. <i>Modern Pathology</i> , 2013, 26, 1632-1641.	5.5	115
23	Progressive methylation during the serrated neoplasia pathway of the colorectum. <i>Modern Pathology</i> , 2005, 18, 170-178.	5.5	112
24	Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. <i>Oncology Reports</i> , 2011, 25, 1517-24.	2.6	111
25	Identification of <i>ROS1</i> rearrangement in gastric adenocarcinoma. <i>Cancer</i> , 2013, 119, 1627-1635.	4.1	108
26	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. <i>Journal of Cancer</i> , 2016, 7, 484-489.	2.5	106
27	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. <i>Cancer Discovery</i> , 2021, 11, 2168-2185.	9.4	105
28	Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2014, 124, 5145-5158.	8.2	105
29	Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. <i>PLoS Genetics</i> , 2015, 11, e1005467.	3.5	104
30	Multiple Gastrointestinal Stromal Tumors: Clinicopathologic and Genetic Analysis of 12 Patients. <i>American Journal of Surgical Pathology</i> , 2007, 31, 224-232.	3.7	102
31	Methylation reveals a niche: stem cell succession in human colon crypts. <i>Oncogene</i> , 2002, 21, 5441-5449.	5.9	100
32	Oncogenic <i>ALK</i> Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. <i>Clinical Cancer Research</i> , 2016, 22, 3831-3840.	7.0	99
33	KRAS Mutations in Traditional Serrated Adenomas From Korea Herald an Aggressive Phenotype. <i>American Journal of Surgical Pathology</i> , 2010, 34, 667-675.	3.7	98
34	Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. , 2021, 9, e002467.		97
35	Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery. <i>PLoS ONE</i> , 2014, 9, e90133.	2.5	96
36	Differential Proteomic Analysis of Human Saliva using Tandem Mass Tags Quantification for Gastric Cancer Detection. <i>Scientific Reports</i> , 2016, 6, 22165.	3.3	96

#	ARTICLE	IF	CITATIONS
37	Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. <i>Modern Pathology</i> , 2008, 21, 1533-1541.	5.5	88
38	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015, 6, 40360-40369.	1.8	85
39	Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer. <i>Endoscopy</i> , 2015, 47, 784-793.	1.8	84
40	Gastrointestinal Stromal Tumors in Koreans: It's Incidence and the Clinical, Pathologic and Immunohistochemical Findings. <i>Journal of Korean Medical Science</i> , 2005, 20, 977.	2.5	83
41	Genetic evidence for the multi-step progression of mixed glandular and neuroendocrine gastric carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 85-93.	2.8	80
42	Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. <i>Frontiers in Immunology</i> , 2018, 9, 2012.	4.8	79
43	The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. <i>BMC Cancer</i> , 2011, 11, 344.	2.6	76
44	The prognostic significance of tumor-associated stroma in invasive breast carcinoma. <i>Tumor Biology</i> , 2012, 33, 1573-1580.	1.8	76
45	Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. <i>Modern Pathology</i> , 2013, 26, 677-684.	5.5	76
46	High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e38892.	2.5	72
47	Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. <i>British Journal of Surgery</i> , 2015, 102, 1394-1401.	0.3	70
48	Clinical Presentation and Risk Factors for Cytomegalovirus Colitis in Immunocompetent Adult Patients. <i>Clinical Infectious Diseases</i> , 2015, 60, e20-e26.	5.8	70
49	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. <i>Modern Pathology</i> , 2016, 29, 1095-1103.	5.5	70
50	Small Submucosal Tumors of the Stomach: Differentiation of Gastric Schwannoma from Gastrointestinal Stromal Tumor with CT. <i>Korean Journal of Radiology</i> , 2012, 13, 425.	3.4	68
51	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	1.8	68
52	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. <i>Pathology Research and Practice</i> , 2020, 216, 152881.	2.3	67
53	Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. <i>Journal of Gastric Cancer</i> , 2016, 16, 1.	2.5	66
54	Enhanced Stem Cell Survival in Familial Adenomatous Polyposis. <i>American Journal of Pathology</i> , 2004, 164, 1369-1377.	3.8	65

#	ARTICLE	IF	CITATIONS
55	MicroRNA Expression Profiles in Gastric Carcinogenesis. <i>Scientific Reports</i> , 2018, 8, 14393.	3.3	65
56	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	2.8	62
57	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , 2017, 8, 13320-13328.	1.8	60
58	DOG1 and PKC- $\zeta$ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2011, 24, 866-875.	5.5	58
59	Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the Era of Precision Medicine. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 137-146.	2.8	58
60	Prognostic implications of microsatellite genotypes in gastric carcinoma. <i>International Journal of Cancer</i> , 2000, 89, 378-383.	5.1	57
61	Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 491-500.	2.8	57
62	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015, 6, 28211-28222.	1.8	57
63	Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer. <i>Clinical Chemistry</i> , 2018, 64, 1513-1521.	3.2	56
64	Glomus Tumor of the Stomach: A Clinicopathologic Analysis of 10 Cases and Review of the Literature. <i>Gut and Liver</i> , 2012, 6, 52-57.	2.9	56
65	P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients. <i>Translational Oncology</i> , 2011, 4, 345-349.	3.7	54
66	The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. <i>Oncotarget</i> , 2016, 7, 7940-7951.	1.8	54
67	Molecular Testing for Gastrointestinal Cancer. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 103-121.	1.1	54
68	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	7.0	54
69	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4001-4001.	1.6	53
70	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015, 6, 39028-39035.	1.8	53
71	Current Trends in the Epidemiological and Pathological Characteristics of Gastrointestinal Stromal Tumors in Korea, 2003-2004. <i>Journal of Korean Medical Science</i> , 2010, 25, 853.	2.5	52
72	Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. <i>ESMO Open</i> , 2018, 3, e000326.	4.5	52

#	ARTICLE	IF	CITATIONS
73	Early Tumor Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. <i>Cancer Discovery</i> , 2022, 12, 984-1001.	9.4	52
74	Prognostic Stratification of High-risk Gastrointestinal Stromal Tumors in the Era of Targeted Therapy. <i>Annals of Surgery</i> , 2008, 247, 1011-1018.	4.2	48
75	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 630-651.	9.4	48
76	PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. <i>Modern Pathology</i> , 2021, 34, 1719-1727.	5.5	48
77	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015, 6, 25619-25630.	1.8	48
78	Outcomes of endoscopic submucosal dissection for differentiated-type early gastric cancer with histological heterogeneity. <i>Gastric Cancer</i> , 2015, 18, 618-626.	5.3	47
79	Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. <i>Journal of Gastroenterology</i> , 2017, 52, 594-601.	5.1	47
80	Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. <i>Oncotarget</i> , 2015, 6, 38372-38380.	1.8	47
81	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , 2016, 7, 43492-43503.	1.8	45
82	Genotyping Possible Polymorphic Variants of Human Mismatch Repair Genes in Healthy Korean Individuals and Sporadic Colorectal Cancer Patients. <i>Familial Cancer</i> , 2002, 3, 129-137.	1.9	44
83	The Korean guideline for gastric cancer screening. <i>Journal of the Korean Medical Association</i> , 2015, 58, 373.	0.3	44
84	Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor <i>RNF43</i> in early gastric carcinogenesis. <i>Journal of Pathology</i> , 2016, 240, 304-314.	4.5	44
85	Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea. <i>Cancer Research and Treatment</i> , 2012, 44, 85-96.	3.0	43
86	The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer. <i>Scientific Reports</i> , 2015, 5, 9289.	3.3	43
87	Tracing origin of serrated adenomas with BRAF and KRAS mutations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 447, 597-602.	2.8	42
88	Acquired resistance to LY2874455 in <i>FGFR2</i> -amplified gastric cancer through an emergence of novel <i>FGFR2-ACSL5</i> fusion. <i>Oncotarget</i> , 2017, 8, 15014-15022.	1.8	42
89	PKC $\delta$ expression in gastrointestinal stromal tumor. <i>Modern Pathology</i> , 2006, 19, 1480-1486.	5.5	41
90	Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic <i>in situ</i> hybridization. <i>Pathology International</i> , 2008, 58, 17-25.	1.3	41

#	ARTICLE	IF	CITATIONS
91	<sc> Lynch-like syndrome: Characterization and comparison with EPCAM deletion carriers. International Journal of Cancer, 2015, 136, 1568-1578.	5.1	40
92	Bridging genomics and phenomics of gastric carcinoma. International Journal of Cancer, 2019, 145, 2407-2417.	5.1	40
93	Human epidermal growth factor receptor 2 testing in gastric cancer: Recommendations of an Asia-Pacific Task Force. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 297-307.	1.1	39
94	Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Targeted Oncology, 2015, 10, 597-601.	3.6	39
95	Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas. Pathology, 2012, 44, 216-220.	0.6	37
96	The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing. Scientific Reports, 2016, 6, 26732.	3.3	37
97	Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma. Gastric Cancer, 2016, 19, 852-859.	5.3	37
98	A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers. PLoS ONE, 2013, 8, e54644.	2.5	37
99	Endoscopic Submucosal Dissection of Early Gastric Cancer. Gut and Liver, 2011, 5, 418-426.	2.9	36
100	Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer. PLoS ONE, 2013, 8, e82770.	2.5	36
101	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2018, 17, 838-848.	4.1	36
102	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget, 2016, 7, 4024-4035.	1.8	36
103	Tracing ancestry with methylation patterns: most crypts appear distantly related in normal adult human colon. BMC Gastroenterology, 2004, 4, 8.	2.0	35
104	High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations. PLoS ONE, 2012, 7, e41655.	2.5	35
105	A Large Cohort of Consecutive Patients Confirmed Frequent HER2 Positivity in Gastric Carcinomas with Advanced Stages. Annals of Surgical Oncology, 2013, 20, 477-484.	1.5	35
106	Anti-Helicobacter pylori Antibody Profiles in Epstein-Barr virus (EBV) Positive and EBV Negative Gastric Cancer. Helicobacter, 2016, 21, 153-157.	3.5	35
107	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. Translational Oncology, 2018, 11, 37-42.	3.7	35
108	Fractional allelic loss in gastric carcinoma correlates with growth patterns. Oncogene, 1998, 17, 2655-2659.	5.9	34

#	ARTICLE	IF	CITATIONS
109	Cyclooxygenase-2 Is an Independent Prognostic Factor in Gastric Carcinoma Patients Receiving Adjuvant Chemotherapy and Is Not Associated with EBV Infection. <i>Clinical Cancer Research</i> , 2009, 15, 291-298.	7.0	34
110	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2527-2536.	4.1	34
111	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016, 16, 105.	2.5	34
112	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. <i>Gastric Cancer</i> , 2021, 24, 457-466.	5.3	34
113	High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer. <i>PLoS ONE</i> , 2014, 9, e111693.	2.5	34
114	ESOPHAGEAL PARAKERATOSIS MIMICKING ENDOSCOPIC APPEARANCE OF SUPERFICIAL ESOPHAGEAL NEOPLASTIC LESION SUCH AS DYSPLASIA. <i>Digestive Endoscopy</i> , 2012, 24, 117-119.	2.3	33
115	Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. <i>Investigational New Drugs</i> , 2013, 31, 1580-1586.	2.6	33
116	HER2-positive gastric cancer with concomitant <i>MET</i> and/or <i>EGFR</i> overexpression: A distinct subset of patients for dual inhibition therapy. <i>International Journal of Cancer</i> , 2015, 136, 1629-1635.	5.1	33
117	Characterization of Human Salivary Extracellular RNA by Next-generation Sequencing. <i>Clinical Chemistry</i> , 2018, 64, 1085-1095.	3.2	33
118	Plexiform Angiomyxoid Myofibroblastic Tumor of the Stomach: Report of Two Cases and Review of the Literature. <i>Korean Journal of Pathology</i> , 2012, 46, 292.	1.3	33
119	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. <i>Oncolmmunology</i> , 2017, 6, e1356150.	4.6	32
120	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. <i>Oncotarget</i> , 2017, 8, 42478-42486.	1.8	32
121	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015, 6, 24320-24332.	1.8	32
122	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. , 2022, 10, e005041.		31
123	Clinical significance of gastritis cystica profunda and its association with Epstein-Barr virus in gastric cancer. <i>Cancer</i> , 2012, 118, 5227-5233.	4.1	30
124	Endoscopic Resection for Undifferentiated Early Gastric Cancer: Focusing on Histologic Discrepancies Between Forceps Biopsy-Based and Endoscopic Resection Specimen-Based Diagnosis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2536-2543.	2.3	30
125	Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. <i>Investigational New Drugs</i> , 2014, 32, 535-541.	2.6	30
126	Composite glandular-endocrine cell carcinomas of the stomach: clinicopathologic and methylation study. <i>Apmis</i> , 2005, 113, 569-576.	2.0	29



#	ARTICLE	IF	CITATIONS
127	Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. <i>Acta Oncologica</i> , 2012, 51, 528-536.	1.8	29
128	Integrated genomic analyses identify frequent gene fusion events and <i>VHL</i> inactivation in gastrointestinal stromal tumors. <i>Oncotarget</i> , 2016, 7, 6538-6551.	1.8	29
129	Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun. <i>Oncotarget</i> , 2015, 6, 20190-20203.	1.8	29
130	Management Strategy for Small Duodenal Carcinoid Tumors: Does Conservative Management with Close Follow-Up Represent an Alternative to Endoscopic Treatment?. <i>Digestion</i> , 2013, 87, 247-253.	2.3	28
131	Feasibility and Diagnostic Yield of Endoscopic Ultrasonography-Guided Fine Needle Biopsy With a New Core Biopsy Needle Device in Patients With Gastric Subepithelial Tumors. <i>Medicine (United States)</i> , 2015, 94, e1622.	1.0	28
132	Preoperative Predictive Factors for Gastrointestinal Stromal Tumors: Analysis of 375 Surgically Resected Gastric Subepithelial Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 631-638.	1.7	28
133	MicroRNA signatures associated with lymph node metastasis in intramucosal gastric cancer. <i>Modern Pathology</i> , 2021, 34, 672-683.	5.5	28
134	Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene. <i>PLoS ONE</i> , 2012, 7, e34456.	2.5	28
135	Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability. , 1999, 82, 782-788.		27
136	Lymphoepithelioma-like carcinoma: A distinct type of gastric cancer. <i>Journal of Surgical Research</i> , 2015, 194, 458-463.	1.6	27
137	Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 293-299.	1.1	26
138	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	1.9	26
139	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. <i>Translational Cancer Research</i> , 2020, 9, 3367-3374.	1.0	26
140	Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea. <i>Journal of Korean Medical Science</i> , 2010, 25, 1543.	2.5	25
141	Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. <i>Targeted Oncology</i> , 2013, 8, 271-280.	3.6	25
142	Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling. <i>Scientific Reports</i> , 2014, 4, 3623.	3.3	25
143	Gastrointestinal stromal tumours: Correlation of modified NIH risk stratification with diffusion-weighted MR imaging as an imaging biomarker. <i>European Journal of Radiology</i> , 2015, 84, 33-40.	2.6	25
144	Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 347-351.	3.8	25

#	ARTICLE	IF	CITATIONS
145	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. <i>Gastric Cancer</i> , 2018, 21, 1064-1070.	5.3	25
146	A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth. <i>Oncotarget</i> , 2016, 7, 28670-28683.	1.8	25
147	Biomarkers for gastric cancer: molecular classification revisited. <i>Precision and Future Medicine</i> , 2017, 1, 59-68.	1.6	25
148	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 447-56.	1.4	25
149	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , 2014, 4, 7592.	3.3	24
150	The NEXT-1 (Next generation pERsonalized tX with mulTI-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	1.8	24
151	Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters. <i>Cancer Research and Treatment</i> , 2015, 47, 813-822.	3.0	24
152	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. <i>Translational Oncology</i> , 2017, 10, 469-475.	3.7	23
153	Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma. <i>Gastric Cancer</i> , 2021, 24, 858-867.	5.3	23
154	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. <i>Oncotarget</i> , 2017, 8, 66305-66315.	1.8	23
155	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	1.8	23
156	Mucinous Gastric Cancer Presents with More Advanced Tumor Stage and Weaker $\beta$ -Catenin Expression than Nonmucinous Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 3053-3058.	1.5	22
157	Lymphovascular invasion and lymph node metastasis rates in papillary adenocarcinoma of the stomach: implications for endoscopic resection. <i>Gastric Cancer</i> , 2018, 21, 680-688.	5.3	22
158	Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis. <i>Journal of Clinical Pathology</i> , 2018, 71, 221-227.	2.0	22
159	NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. <i>Journal of Cancer</i> , 2018, 9, 3032-3037.	2.5	22
160	Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. <i>Gastric Cancer</i> , 2019, 22, 363-368.	5.3	22
161	CCNE1 amplification is associated with liver metastasis in gastric carcinoma. <i>Pathology Research and Practice</i> , 2019, 215, 152434.	2.3	22
162	Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor. <i>Tumor Biology</i> , 2012, 33, 1645-1651.	1.8	21

#	ARTICLE	IF	CITATIONS
163	A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single-Nucleotide Variant Detection. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 651-658.	2.8	21
164	High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. <i>Pathology Research and Practice</i> , 2020, 216, 152878.	2.3	21
165	Epstein-Barr virus-associated lymphoepithelioma-like early gastric carcinomas and endoscopic submucosal dissection: Case series. <i>World Journal of Gastroenterology</i> , 2014, 20, 1365.	3.3	21
166	Clinicopathological Features and Prognosis of Mixed-Type T1a Gastric Cancer Based on Lauren's Classification. <i>Annals of Surgical Oncology</i> , 2016, 23, 784-791.	1.5	20
167	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). <i>Journal of Cancer</i> , 2017, 8, 1395-1399.	2.5	20
168	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. <i>Frontiers in Oncology</i> , 2019, 9, 212.	2.8	20
169	MMR protein immunohistochemistry and microsatellite instability in gastric cancers. <i>Pathology</i> , 2019, 51, 110-113.	0.6	20
170	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	8.2	20
171	PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. <i>Cancers</i> , 2021, 13, 4659.	3.7	20
172	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	3.2	20
173	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245.	1.8	20
174	Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma. <i>Pathology</i> , 2012, 44, 18-23.	0.6	19
175	Predictive factors for lymph node metastasis in early gastric cancer with lymphatic invasion after endoscopic resection. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 4419-4424.	2.4	17
176	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 140-146.	2.3	17
177	Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	2.1	17
178	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. <i>Genome Medicine</i> , 2021, 13, 11.	8.2	17
179	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 66-66.	1.6	17
180	GAGE12 mediates human gastric carcinoma growth and metastasis. <i>International Journal of Cancer</i> , 2015, 136, 2284-2292.	5.1	16

#	ARTICLE	IF	CITATIONS
181	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. <i>ESMO Open</i> , 2016, 1, e000009.	4.5	16
182	Diagnostic group classifications of gastric neoplasms by endoscopic resection criteria before and after treatment: real-world experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 3987-3993.	2.4	16
183	Identification of risk factors for sessile and traditional serrated adenomas of the colon by using big data analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1039-1046.	2.8	16
184	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 243-250.	2.8	16
185	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in <i>MET</i> -Amplified Gastric Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 222-232.	3.0	16
186	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017, 8, 105727-105734.	1.8	16
187	Pituitary Aspergillosis Mimicking Pituitary Tumor. <i>American Journal of Roentgenology</i> , 2000, 175, 1570-1572.	2.2	15
188	Gastrointestinal stromal tumors in children and young adults: a clinicopathologic and molecular genetic study of 22 Korean cases. <i>Apmis</i> , 2013, 121, 938-944.	2.0	15
189	Clinicopathological factors of multiple lateral margin involvement after endoscopic submucosal dissection for early gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 3460-3468.	2.4	15
190	Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers. <i>Pathology Research and Practice</i> , 2022, 233, 153874.	2.3	15
191	PolyA Deletions in Hereditary Nonpolyposis Colorectal Cancer. <i>American Journal of Pathology</i> , 2002, 160, 1503-1506.	3.8	14
192	Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1333-1338.	2.3	14
193	Comparison of Long-Term Outcomes After Non-curative Endoscopic Resection in Older Patients with Early Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2624-2631.	1.5	14
194	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , 2017, 22, 1169-1177.	3.7	14
195	Feasibility of Endoscopic Resection in Early Gastric Cancer with Lymphovascular Invasion. <i>Annals of Surgical Oncology</i> , 2019, 26, 449-455.	1.5	14
196	Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 543.	3.2	14
197	Neuroendocrine tumor in gastric adenoma: a diagnostic pitfall mimicking invasive adenocarcinoma. <i>Diagnostic Pathology</i> , 2012, 7, 102.	2.0	13
198	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 375-383.	3.8	13

#	ARTICLE	IF	CITATIONS
199	PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression. <i>Cancers</i> , 2020, 12, 1724.	3.7	13
200	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 701668.	4.8	13
201	Prognostic Value of Highly Expressed Type VII Collagen (COL7A1) in Patients With Gastric Cancer. <i>Pathology and Oncology Research</i> , 2021, 27, 1609860.	1.9	13
202	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018, 18, 348.	2.5	12
203	Gastric adenocarcinoma with enteroblastic differentiation should be differentiated from hepatoid adenocarcinoma: A study with emphasis on clear cells and clinicopathologic spectrum. <i>Pathology Research and Practice</i> , 2019, 215, 152525.	2.3	12
204	PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study. <i>Pathology Research and Practice</i> , 2021, 218, 153338.	2.3	12
205	Inter-observer Reproducibility in the Pathologic Diagnosis of Gastric Intraepithelial Neoplasia and Early Carcinoma in Endoscopic Submucosal Dissection Specimens: A Multi-center Study. <i>Cancer Research and Treatment</i> , 2019, 51, 1568-1577.	3.0	12
206	Sporadic colorectal carcinomas with low-level microsatellite instability in Korea: Do they form a distinct subgroup with distinguished clinicopathological features?. <i>Journal of Surgical Oncology</i> , 2009, 99, 351-355.	1.7	11
207	CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1099-1106.	1.5	11
208	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1231-1237.	2.5	11
209	LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. <i>Journal of Immunotherapy</i> , 2019, 42, 279-283.	2.4	11
210	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152947.	2.3	11
211	IKK $\mu$ and TBK1 expression in gastric cancer. <i>Oncotarget</i> , 2017, 8, 16233-16242.	1.8	11
212	Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 556-567.	2.4	11
213	Evidence for two modes of allelic loss: multifocal analysis on both early and advanced gastric carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 31-38.	2.8	10
214	Comparison of Three <i>BRAF</i> Mutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples. <i>Korean Journal of Pathology</i> , 2013, 47, 348.	1.3	10
215	A Risk Prediction Model Based on Lymph-Node Metastasis in Poorly Differentiated "Type Intramucosal Gastric Cancer. <i>PLoS ONE</i> , 2016, 11, e0156207.	2.5	10
216	Neurofibroma of the Colon: A Diagnostic Mimicker of Gastrointestinal Stromal Tumor. <i>Case Reports in Gastroenterology</i> , 2017, 10, 674-678.	0.6	10

#	ARTICLE	IF	CITATIONS
217	Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases. <i>Histopathology</i> , 2017, 71, 805-812.	2.9	10
218	One-dimensional and 2-dimensional tumor size measurement for prediction of lymph node metastasis in differentiated early gastric cancer with minute submucosal invasion. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 730-736.	1.0	10
219	Indication for endoscopic treatment based on the risk of lymph node metastasis in patients with Siewert type II/III early gastric cancer. <i>Gastric Cancer</i> , 2018, 21, 672-679.	5.3	10
220	Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. <i>Scientific Reports</i> , 2018, 8, 13887.	3.3	10
221	MET is overexpressed in microsatellite instability-high gastric carcinoma. <i>Pathology Research and Practice</i> , 2019, 215, 433-438.	2.3	10
222	Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. <i>European Journal of Surgical Oncology</i> , 2020, 46, 189-194.	1.0	10
223	Deep learning-based virtual cytokeratin staining of gastric carcinomas to measure tumor-stroma ratio. <i>Scientific Reports</i> , 2021, 11, 19255.	3.3	10
224	Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. <i>Cancer Research and Treatment</i> , 2015, 47, 738-746.	3.0	10
225	Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer with Undifferentiated-Type Histology: A Clinical Simulation Using a Non-Selected Surgical Cohort. <i>Gut and Liver</i> , 2018, 12, 263-270.	2.9	10
226	EBV infection and mismatch repair deficiency mediated by loss of hMLH1 expression contribute independently to the development of multiple synchronous gastric carcinomas. <i>Journal of Surgical Oncology</i> , 2012, 106, 777-782.	1.7	9
227	Tumor size predicts survival in mucinous gastric carcinoma. <i>Journal of Surgical Oncology</i> , 2012, 106, 757-764.	1.7	9
228	Silent Colonic Malakoplakia in a Living-Donor Kidney Transplant Recipient Diagnosed during Annual Medical Examination. <i>Korean Journal of Pathology</i> , 2013, 47, 163.	1.3	9
229	Exuberant squamous metaplasia of the gastric mucosa in a patient with gastric adenocarcinoma. <i>Diagnostic Pathology</i> , 2015, 10, 46.	2.0	9
230	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 3172-3178.	2.5	9
231	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 612-622.	2.8	9
232	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. <i>Radiotherapy and Oncology</i> , 2020, 152, 19-25.	0.6	9
233	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679.	3.2	9
234	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 107492-107499.	1.8	9

#	ARTICLE	IF	CITATIONS
235	PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors. <i>Journal of Pathology and Translational Medicine</i> , 2015, 49, 23-29.	1.1	9
236	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1153-1161.	3.0	9
237	Serrated adenoma of the stomach: a clinicopathologic, immunohistochemical, and molecular study of nine cases. <i>Histology and Histopathology</i> , 2013, 28, 453-62.	0.7	9
238	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015, 8, 288-294.	3.7	8
239	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019, 12, 597-601.	3.7	8
240	RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. <i>Scientific Reports</i> , 2019, 9, 19439.	3.3	8
241	Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 414-419.	2.5	8
242	Gastric Inverted Polyps—Distinctive Subepithelial Lesions of the Stomach. <i>American Journal of Surgical Pathology</i> , 2021, 45, 680-689.	3.7	8
243	Profiling of activated receptor tyrosine kinases in advanced gastric cancers identifies patients with poor prognosis. <i>Journal of Clinical Oncology</i> , 2012, 30, 4011-4011.	1.6	8
244	Clinical usefulness of microsatellite instability test in Korean young patients with high-risk features associated with adenoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 378-383.	1.5	7
245	Young Age and Risk of Lymph Node Metastasis in Differentiated Type Early Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2713-2719.	1.5	7
246	Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue. <i>Scientific Reports</i> , 2019, 9, 9675.	3.3	7
247	A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. <i>Frontiers in Oncology</i> , 2020, 10, 225.	2.8	7
248	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	7
249	Peritumoral lymphoid cuff correlates well with lymph node enlargement in gastrointestinal schwannomas. <i>Oncotarget</i> , 2018, 9, 12591-12598.	1.8	7
250	Integrated genomic approaches identify upregulation of <i>SCRN1</i> as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. <i>Oncotarget</i> , 2016, 7, 13797-13809.	1.8	7
251	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	1.3	7
252	High Frequency of Juxtamembrane Domain <i>ERBB2</i> Mutation in Gastric Cancer. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 105-112.	2.0	7

#	ARTICLE	IF	CITATIONS
253	Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas. <i>Diagnostic Pathology</i> , 2013, 8, 121.	2.0	6
254	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1198-1206.	1.4	6
255	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. <i>Translational Oncology</i> , 2019, 12, 1488-1495.	3.7	6
256	Correlation between RICTOR overexpression and amplification in advanced solid tumors. <i>Pathology Research and Practice</i> , 2020, 216, 152734.	2.3	6
257	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152820.	2.3	6
258	Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 42-51.	3.0	6
259	Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer. <i>European Radiology</i> , 2022, 32, 1-11.	4.5	6
260	Poorly differentiated component in gastric pinch biopsies predicts submucosal invasion. <i>Diagnostic Pathology</i> , 2014, 9, 34.	2.0	5
261	IL-7R <sup>hi</sup> low CD8 <sup>+</sup> T Cells from Healthy Individuals Are Anergic with Defective Glycolysis. <i>Journal of Immunology</i> , 2020, 205, 2968-2978.	0.8	5
262	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. <i>Cancers</i> , 2020, 12, 943.	3.7	5
263	Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3536-3536.	1.6	5
264	Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer. <i>Cancers</i> , 2021, 13, 2316.	3.7	5
265	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	2.5	5
266	Novel mechanism of a CDH1 splicing mutation in a Korean patient with signet ring cell carcinoma. <i>BMB Reports</i> , 2011, 44, 725-729.	2.4	5
267	Stage IV early gastric cancer: two cases with microsatellite instability. <i>Langenbeck's Archives of Surgery</i> , 2007, 393, 105-109.	1.9	4
268	Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours. <i>Pathology</i> , 2012, 44, 460-464.	0.6	4
269	Measurement of tumor volume is not superior to diameter for prediction of lymph node metastasis in early gastric cancer with minute submucosal invasion. <i>Oncotarget</i> , 2017, 8, 113758-113765.	1.8	4
270	CDH1 mutations in gastric cancers are not associated with family history. <i>Pathology Research and Practice</i> , 2020, 216, 152941.	2.3	4



#	ARTICLE	IF	CITATIONS
271	Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 8908-8915.	1.5	4
272	Highly sensitive duplex MSI test and BAT40 germline polymorphism. <i>Apmis</i> , 2021, 129, 607-615.	2.0	4
273	Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer. <i>Precision and Future Medicine</i> , 2019, 3, 165-175.	1.6	4
274	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4508-4515.	0.0	4
275	A comparative study of telomerase activity and cytologic diagnosis in malignant ascites. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2013, 35, 146-51.	0.2	4
276	Is endoscopic resection an alternative to surgery for early low-risk submucosal gastric cancers: analysis of a large surgical database. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 1614-1620.	2.4	3
277	Effect of age on the clinical outcomes of patients with early gastric cancer with undifferentiated-type histology. <i>Surgery</i> , 2019, 165, 802-807.	1.9	3
278	Pathologic analyses of peritoneal nodules in gastric cancer patients during surgery—A single cancer center experience with diagnostic pitfalls. <i>Pathology Research and Practice</i> , 2019, 215, 195-199.	2.3	3
279	Outcomes of endoscopic submucosal dissection for intestinal-type adenocarcinoma with anastomosing glands of the stomach. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 50-55.	2.8	3
280	Dysregulated miRNA in a cancer-prone environment: A study of gastric non-neoplastic mucosa. <i>Scientific Reports</i> , 2020, 10, 6600.	3.3	3
281	Favorable Long-Term Outcomes of Endoscopic Submucosal Dissection for Differentiated-Type-Predominant Early Gastric Cancer with Histological Heterogeneity. <i>Journal of Clinical Medicine</i> , 2020, 9, 1064.	2.4	3
282	Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial—A feasibility analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 11534-11534.	1.6	3
283	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signed gastric cancer patients: First arm of the umbrella trial in GC through the molecular screening, VIKTORY trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 4061-4061.	1.6	3
284	Assessment of Gastritis Using Operative Link for Gastritis Assessment System. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2013, 13, 20.	0.4	3
285	Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers. <i>BMC Medical Genomics</i> , 2022, 15, 25.	1.5	3
286	Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 856444.	2.8	3
287	Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation. <i>Pathology</i> , 2012, 44, 260-261.	0.6	2
288	Recent advances in endoscopic diagnosis and treatment of gastric cancer. <i>Journal of the Korean Medical Association</i> , 2015, 58, 191.	0.3	2

#	ARTICLE	IF	CITATIONS
289	Factors Associated With Host Immune Response and Number of Lymph Nodes: A Large Retrospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 3621-3628.	1.5	2
290	DNA-protein biomarkers for immunotherapy in the era of precision oncology. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 26-32.	1.1	2
291	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3104-3104.	1.6	2
292	Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial. <i>Precision and Future Medicine</i> , 2019, 3, 24-29.	1.6	2
293	Negative Biopsy after Referral for Biopsy-Proven Gastric Cancer. <i>Gut and Liver</i> , 2016, 10, 63.	2.9	2
294	Single patient classifier as a prognostic biomarker in pT1N1 gastric cancer: Results from two large Korean cohorts. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 583-591.	2.2	2
295	Risk-Scoring System for Prediction of Non-Curative Endoscopic Submucosal Dissection Requiring Additional Gastrectomy in Patients with Early Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2021, 21, 368.	2.5	2
296	Gastric Carcinoma: Morphologic Classifications and Molecular Changes. , 0, , .		1
297	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 2173-2178.	2.5	1
298	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. <i>Journal of Cancer</i> , 2017, 8, 730-736.	2.5	1
299	Interchangeability of PD-L1 laboratory-developed test by 22C3 antibody concentrate among ihc platforms in gastric cancer. <i>Pathology</i> , 2020, 52, S120.	0.6	1
300	Clinical feasibility and oncologic safety of primary endoscopic submucosal dissection for clinical submucosal invasive early gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3051-3061.	2.5	1
301	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15610-e15610.	1.6	1
302	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14501-e14501.	1.6	1
303	Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16029-e16029.	1.6	1
304	Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein-Barr virus positive gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15509-e15509.	1.6	1
305	Mesenteric Fibromatosis Mimicking Recurrence after Distal Gastrectomy for Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2010, 10, 79.	2.5	1
306	Profiling of circulating tumor cells isolated from 105 metastatic gastric cancer patients revealed HER2 overexpression/activation for potential use in clinical setting.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10535-10535.	1.6	1

#	ARTICLE	IF	CITATIONS
307	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. Journal of Clinical Oncology, 2014, 32, 4008-4008.	1.6	1
308	Filiform serrated adenoma: authorsâ€™ reply. Pathology, 2012, 44, 386.	0.6	0
309	Gastrointestinal stromal tumour with CDKN2A deletions: a report of three cases. Pathology, 2019, 51, 537-539.	0.6	0
310	PTEN Protein losses and loss-of-function genetic variants in gastric cancers: the relationship with microsatellite instability, EBV, and PD-L1 expression. Pathology, 2020, 52, S120.	0.6	0
311	ASO Video Abstract: Microsatellite Instability and the Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancerâ€™A Multi-cohort Study. Annals of Surgical Oncology, 2021, 28, 688.	1.5	0
312	Author's Correction. American Journal of Roentgenology, 2000, 175, 556-556.	2.2	0
313	Esophageal Gland Duct Adenoma. Korean Journal of Pathology, 2011, 45, S45.	1.3	0
314	SSTR2A Protein Expression in Neuroendocrine Neoplasms of the Colorectum. Korean Journal of Pathology, 2011, 45, 276.	1.3	0
315	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN<sup>â„“</sup>).. Journal of Clinical Oncology, 2015, 33, e22173-e22173.	1.6	0
316	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. Journal of Clinical Oncology, 2015, 33, e22241-e22241.	1.6	0
317	Development and validation of sensitive and selective biomarker for early detection and prognostic system of colorectal cancer using aptamer biochip.. Journal of Clinical Oncology, 2015, 33, e22124-e22124.	1.6	0
318	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. Journal of Clinical Oncology, 2017, 35, e14622-e14622.	1.6	0
319	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	1.6	0
320	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	1.6	0
321	IL-7RÎ± &lt;sup>&gt;low&lt;/sup>; CD8 &lt;sup>&gt;+&lt;/sup>; T Cells from Healthy Individuals Are Anergic with Defective Glycolysis. SSRN Electronic Journal, 0, , .	0.4	0
322	Abstract 1107: LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. , 2019, , .		0
323	Abstract 3605: O-linked N-acetylglucosamine transferase as a potential therapeutic target for metastatic gastric cancer. , 2019, , .		0
324	Novel target discovery in pembrolizumab-resistant gastric cancer using a comprehensive RNA-seq analysis pipeline.. Journal of Clinical Oncology, 2020, 38, e16541-e16541.	1.6	0

#	ARTICLE	IF	CITATIONS
325	Abstract 2370: Elevated levels of anti-Epstein Barr virus (EBV) antibodies in EBV-associated gastric carcinoma. , 2020, , .		0
326	Mycobiome analysis in fungal infected formalin-fixed and paraffin-embedded tissues for identification of pathogenic fungi: a pilot study. F1000Research, 0, 9, 758.	1.6	0
327	Two Gastric Cancers With Uncommon ALK Fusion Diagnosed With Comprehensive Panel Sequencing and Confirmed With Companion Diagnostic Assay. AJSP Review and Reports, 2022, 27, 9-12.	0.1	0
328	Abstract 3605: O-linked N-acetylglucosamine transferase as a potential therapeutic target for metastatic gastric cancer. , 2019, , .		0
329	Prevalence of MET aberration using next generation sequencing in oncology clinic: A real-world experience.. Journal of Clinical Oncology, 2022, 40, e16099-e16099.	1.6	0